Cardioprotective interventions for cancer patients receiving anthracyclines

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 6, 2011, Pages

  van Dalen, Elvira C ^a   Caron, Huib N ^a   Dickinson, Heather O ^b   Kremer, Leontien C M ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMIFOSTINE; ANTHRACYCLINE; ASCORBIC ACID; CARNITINE; CARVEDILOL; DAUNORUBICIN; DOXORUBICIN; PHENETHYLAMINE; PLACEBO; RAZOXANE; UBIDECARENONE; ANTINEOPLASTIC ANTIBIOTIC; CARDIOTONIC AGENT;

ALOPECIA; ANEMIA; ANOREXIA; CANCER PATIENT; CLINICAL EFFECTIVENESS; DIARRHEA; FEVER; HEART FAILURE; HEART INJURY; HEART PROTECTION; HUMAN; INJECTION SITE PAIN; LEUKEMIA; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHLEBITIS; PLATELET COUNT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; CELL PROTECTION; CHEMICALLY INDUCED DISORDER; HEART DISEASE; META ANALYSIS; NEOPLASM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTONIC AGENTS; CYTOPROTECTION; HEART DISEASES; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAZOXANE;

EID: 80052044499     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003917.pub4     Document Type: Review

References (101)

1. Galetta F, Franzoni F, Cervetti G, Cecconi N, Carpi A, Petrini M, et al.Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomedicine & Pharmacotherapy 2005;59:541-4.
2. Gallegos-Castorena S, Martínez-Avalos A, Mohar-Betancourt A, Guerrero-Avendaño G, Zapata-Tarrés M, Medina-Sansón A. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatric Hematology and Oncology 2007;24:403-8.
3. Iarussi D, Auricchio U, Agretto A, Murano A, Giuliano M, Casale F, et al.Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-hodgkin lymphoma. Molecular Aspects of Medicine 1994;15 Suppl:207-12.
4. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al.Protective effects of carvedilol against anthracycline-induced cardiomyopathy. Journal of the American College of Cardiology 2006;48:2258-62.
5. Kraft J, Grille W, Appelt M, Hossfeld DK, Eichelbaum M, Koslowski B, et al.Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial. Haematology and Blood Transfusion 1990;33:566-70.
6. Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, et al.Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. Journal of Clinical Oncology 2008;26:1106-11.
7. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al.The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. The New England Journal of Medicine 2004;351:145-53.
8. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, et al.Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncology 2010;11:950-61.
9. Lopez M, Vici P, Di Lauro L, Conti F, Paoletti G, Ferraironi A, et al.Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. Journal of Clinical Oncology 1998;16:86-92.
10. Marty M, Espie M, Llombart A, Monnier A, Rapoport BL, Stahalova V. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Annals of Oncology 2006;17:614-22.
11. Milei J, Marantz A, Ale J, Vazquez A, Buceta JE. Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study. Cancer Drug Delivery 1987;4:129-36.
12. Myers C, Bonow R, Palmeri S, Jenkins J, Corden B, Locker G, et al.A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Seminars in Oncology 1983;10 Suppl 1(1):53-5.
13. Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, et al.A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate-and high-risk Hodgkin lymphoma: the results of P9425. Blood 2009;114:2051-9.
14. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, et al.ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. Journal of Clinical Oncology 1992;10:117-27.
15. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al.Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. Journal of Clinical Oncology 1997;15:1318-32.
16. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al.Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. Journal of Clinical Oncology 1997;15:1318-32.
17. Venturini M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, et al.Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. Journal of Clinical Oncology 1996;14:3112-20.
18. Wagdi PH, Rouvinez G, Fluri M, Aeschbacher B, Thoni A, Schefer H, et al.Cardioprotection during chemo-and radiotherapy of malignant diseases -an echocardiographic pilot study [Kardioprotektion bei chemo-und radiotherapie fur maligne erkrankungen -eine echokardiographische pilotstudie]. Schweizerische Rundschau fur Medizin (Praxis) 1995;84:1220-3.
19. Waldner R, Laschan C, Lohninger A, Gessner M, Tuchler H, Huemer M, et al.Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. Journal of Cancer Research and Clinical Oncology 2006;132:121-8.
20. Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, Chen CC, et al.Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. Journal of Clinical Oncology 1996;14:362-72.
21. Bates M, Lieu D, Zagari M, Spiers A, Williamson T. A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer. Clinical Therapeutics 1997;19:167-84.
22. Batist G, Norton J, Katki AG, Wagman L, Ferrans VJ, Maher M, et al.Cardiac and red blood cell glutathione peroxidase: results of a prospective randomized trial in patients on total parenteral nutrition. Cancer Research 1985;45:5900-3.
23. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al.Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-81.
24. Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. Journal of Clinical Oncology 1995;13:26-32.
25. Judy WV, Hall JH, Dugan W, Toth PD, Folkers K. Coenzyme Q10 reduction of adriamycin cardiotoxicity. In: Folkers K, Yamamura Y editor(s). Biomedical and clinical aspects of coenzyme Q. Vol. 4, Amsterdam: Elsevier / North-Holland Biomedical Press, 1984:231-41.
26. Massidda B, Fenu MA, Ionta MT, Tronci M, Foddi MR, Montaldo C, et al.Early detection of the anthracycline-induced cardiotoxicity. A non-invasive haemodynamic study. Anticancer Research 1997;17:663-8.
27. Michelotti A, Venturini M, Tibaldi C, Bengala C, Gallo L, Carnino F, et al.Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients. Breast Cancer Research and Treatment 2000;59:133-9.
28. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, et al.Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;103:896-904.
29. Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, et al.Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005;104:2492-8.
30. Neto RPDM, Petrilli AS, Silva CMC, Campos Filho O, Oporto VM, Gomes LDFG, et al.Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane. Arquivos Brasileiros de Cardiologia 2006;87:699-706.
31. Paiva MG, Petrilli AS, Moises VA, Macedo CR, Tanaka C, Campos O. Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography. Pediatric Blood and Cancer 2005;45:902-8.
32. Piccinini F, Monti E, Paracchini L. Protective effect of trimetazidine on the cardiotoxicity of doxorubicin. Concours Medical 1987;109:3479-83.
33. Rosenfeld CS, Weisberg SR, York RM, Jones SE, Spicer DV, Khojasteh A, et al.Prevention of adriamycin cardiomyopathy with dexrazoxane (ADR-529, ICRF-187). Proceedings of ASCO 1992;11:62.
34. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, et al.Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. The New England Journal of Medicine 1988;319:745-52.
35. Speyer JL, Green MD, Sanger J, Zeleniuch-Jacquotte A, Kramer E, Rey M, et al.A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer. Cancer Treatment Reviews 1990;17:161-3.
36. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. Journal of Clinical Oncology 1997;15:1333-40.
37. Tallarico D, Rizzo V, Di Maio F, Petretto F, Bianco G, Placanica G, et al.Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy. Angiology 2003;54:219-27.
38. Tebbi CK, London WB, Friedman F, Villaluna D, De Alarcon PA, Constine LS, et al.Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. Journal of Clinical Oncology 2007;25:493-500.
39. Ten Bokkel-Huinink WW, Rodenhuis S, Schreuder JE, Dubbelman R, Bierhorst F, van Tinteren H, et al.ICRF 187 protects against doxorubicin induced cardiomyopathy. Annals of Oncology 1990;1:106.
40. Tonkin K, Bates M, Lieu D, Arundell E, Williamson TY, Zagari M. Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation. Annals of Cancer Control Research 1996;6:458-73.
41. Unverferth DV, Fertel RH, Balcerzak SP, Magorien RD, O'Dorisio MS. N-Acetylcysteine prevents the doxorubicin-induced decrease of cyclic GMP. Seminars in Oncology 1983;10 Suppl 1(1):49-52.
42. Unverferth DV, Jagadeesh JM, Unverferth BJ, Magorien RD, Leier CV, Balcerzak SP. Attempt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine. Journal of the National Cancer Institute 1983;71:917-20.
43. Vici P, Ferraironi A, Di Lauro L, Carpano S, Conti F, Belli F, et al.Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment. La Clinica Terapeutica 1998;149:15-20.
44. Wagdi P, Fluri M, Aeschbacher B, Fikrle A, Meier B. Cardioprotection in patients undergoing chemo-and/or radiotherapy for neoplastic disease: a pilot study. Japanese Heart Journal 1996;37:353-9.
45. Weisberg SR, Rosenfeld CS, York RM, Jones SE, Spicer DV, Khojasteh A, et al.Dexrazoxane (ADR-529, ICRF-187, Zinecard) protects against doxorubicin induced chronic cardiotoxicity. Proceedings of ASCO 1992;11:91.
46. Weitzman SA, Lorell B, Carey RW, Kaufman S, Stossel TP. Prospective study of tocopherol prophylaxis for anthracycline cardiac toxicity. Current Therapeutic Research 1980;28:682-6.
47. Whittaker JA, Al-Ismail SAD. Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia. British Medical Journal 1984;288:283-4.
48. Whittaker JA, Al-Ismail SAD, Nicholson DM, Saour JN. Doxorubicin cardiotoxicity: attempts at prevention with digoxin and alpha-tocopherol (vitamin E). Clinical Trials Journal 1987;24 Suppl 1:45-55.
49. Cadeddu C, Piras A, Mantovani G, Deidda M, Dessì M, Madeddu C, et al.Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. American Heart Journal 2010;160:487.e1-7.
50. Cardenas R, Mercado CG, Rivela LR, Calderon EC. Effectiveness and safety of dexrazoxane as a cardioprotector in Mexican children with cancer. Medical and Pediatric Oncology 2003;41:PL001.
51. De Berranger E. Results of randomized study on dexrazoxane administration in children with de novo acute leukemia. ASCO Annual Meeting (abstract number 9037). 2006.
52. Feldmann JE, Jones SE, Weisberg SR, Gandars DR, Lyman GH, York RM, et al.Advanced small cell lung cancer treated with CAV (cyclophosphamide + adriamycin + vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR-529, ICRF-187, Zinecard). ASCO Annual Meeting (abstract number 993). 1992.
53. Gu H-S, Li J-Y, Zhang W-H, Zhang Y, Jia S, Fu Y. Clinical observation of hydroprednisone and glutathione in chemotherapy of breast cancer. Chinese Journal of Cancer Prevention and Treatment 2010;17:131-3.
54. Jackowska T, Rokicka-Milewska R, Matysiak M, Balwierz W, Kowalczyk J, Wachowiak J, et al.Assessment of dexrazoxane tolerance in leukemic children receiving anthracyclines. Medical and Pediatric Oncology 2003;41:PD003.
55. Saad El-Din I, El Saban K, Abdel Rahman K, Gabaly M. A randomized clinical trial to evaluate cardioprotective effect of ICRF-187 in children with acute lymphoblastic leukemia. Medical and Pediatric Oncology 2003;41:O109.
56. Ten Bokkel-Huinink WW, Schreuder JE, Dubbelman R, Bierhorst F, Van Tinteren H, Dalesio O, et al.ICRF 187 protects against doxorubicin induced cardiomyopathy. Annals of Oncology (abstract number 221) 1992:114.
57. Phase III randomised study of response-dependent therapy with doxorubicin/bleomycin/vincristine/etoposide (DBVE) with versus without dexrazoxane followed by low-dose involved-field radiotherapy for newly diagnosed stage IA/IIA/IIIA1 childhood Hodgkin's disease. www.controlled-trials.com.
58. Phase III randomised study of doxorubicin and cyclophosphamide with or without dexrazoxane followed by paclitaxel with or without trastuzumab (herceptin) followed by surgery and radiotherapy with or without trastuzumab in women with HER-2+ stage IIIA or IIIB or regional stage IV breast cancer. www.controlled-trials.com.
59. The multi-centers trial for patients with Non-Hodgkin's lymphoma to assess the protective effect of valsartan on chronic cardiotoxicity induced by CHOP. www.controlled-trials.com.
60. Primary prevention of anthracycline-induced cardiotoxicity with L-carnitine in patients with breast cancer (PPACC)-pilot study. www.controlled-trials.com.
61. Enalapril maleate and doxorubicin hydrochloride in treating women with breast cancer. www.controlled-trials.com.
62. Intensive treatment for T-cell acute lymphoblastic leukemia and advanced stage lymphoblastic Non-Hodgkin's lymphoma: a Pediatric Oncology Group Phase III study. www.controlled-trials.com.
63. Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, et al.Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. Journal of Clinical Oncology 2008;26:1106-11.
64. Batist G, Ramakriskan G, Sekhar Rao C, Chandrasekharan A, Gutheil J, Guthrie T, et al.Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breast cancer. Journal of Clinical Oncology 2001;19:1444-54.
65. Bonadonna G, Morfandini S. Cardiac toxicity of daunorubicin. Lancet 1969;1:837.
66. De Leonardis V, Neri B, Bacalli S, Cinelli P. Reduction of cardiac toxicity of anthracyclines by L-Carnitine: preliminary overview of clinical data. International Journal of Clinical Pharmacology Research 1985;5:137-42.
67. Elihu N, Anandasbapathy S, Frishman WH. Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine and dexrazoxane. Journal of Clinical Pharmacology 1998;38:101-5.
68. Garbrecht M, Müllerleile U. Verapamil in the prevention of adriamycin-induced cardiomyopathy. Klinische Wochenschrift 1986;64 Suppl VII:132-4.
69. Guthrie D, Gibson AL. Doxorubicin cardiotoxicity: possible role of digoxin in its prevention. British Medical Journal 1977;2:1447-9.
70. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated September 2006]. John Wiley & Sons, Ltd, In: The Cochrane Library, Issue 4, 2006. Chichester, UK.
71. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org, 2008.
72. Hofmann S, Tuchler H, Bernhart M, Stacher A, Lutz D. A questionnaire suitable for general practice for detection of the health status and quality of life of patients with hemato-oncologic diseases: psychometric properties. The study G "quality of life" of the International Society for Chemo-and Immunotherapy (I.G.C.I.). Wiener Klinische Wochenschrift 1993;105:277-83.
73. Kawasaki S, Akiyama S, Kurokawa T, Kataoka M, Dohmitsu K, Kondoh K, et al.Polyoxyethylene-modified superoxide dismutase reduces side effects of adriamycin and mitomycin C. Japanese Journal of Cancer Research 1992;83:899-906.
74. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacology and Therapeutics 1990;47:219-31.
75. Kremer LCM, van der Pal HJH, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology 2002;13:819-29.
76. Kremer LCM, van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline-induced heart failure in children: a systematic review. Annals of Oncology 2002;13:503-12.
77. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14.
78. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, et al.Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Annals of Internal Medicine 1982;96:133-9.
79. Legha SS, Wang Y, Mackay B, Ewer M, Hortobagyi GN, Benjamin RS, et al.Clinical and pharmacologic investigation of the effects of a-tocopherol on adriamycin cardiotoxicity. Annals of the New York Academy of Sciences 1982;393:411-8.
80. Lipshultz SE, Sallan SE, Giantris AL, Lipsitz SR, Dalton V, Colan SD. 48 hour continuous doxorubicin infusion is not cardioprotective in children assessed 18 months later: the DFCI 91001 ALL protocol. Proceedings of the American Society of Clinical Oncology 1998;17:528a.
81. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, et al.Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncology 2010;11:950-61.
82. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
83. Muggia FM, Green MD. New anthracycline antitumor antibiotics. Critical Reviews in Oncology/Hematology 1991;11:43-64.
84. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, et al.Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. Journal of Clinical Oncology 1997;15:987-93.
85. Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Seminars in Oncology 1998;25 Suppl 10:10-4.
86. Odaimi M, Ajani J. High-dose chemotherapy. American Journal of Clinical Oncology 1987;10:123-32.
87. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al.Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982;5:649-55.
88. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
89. Pierga JY, Robain M, Jouve M, Asselain B, Dieras V, Beuzeboc P, et al.Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients. Annals of Oncology 2001;12:231-7.
90. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, et al.Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia 2010;24(2):355-70.
91. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Annals of Internal Medicine 1996;125:47-58.
92. Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, et al.Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors. American Heart Journal 2001;142:577-85.
93. Singal PK, Siveski-Iliskovic N, Hill M, Thomas TP, Li T. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. Journal of Molecular and Cellular Cardiology 1995;27:1055-62.
94. Tuchler H, Hofmann S, Bernhart M, Brugiatelli M, Chrobak L, Franke A, et al.A short multilingual quality of life questionnaire -practicability, reliability and interlingual homogeneity. Quality of Life Research 1992;1:107-17.
95. Van Acker FAA, Van Acker SABE, Kramer K, Haenen GR, Bast A, van der Vijgh WJ. 7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week. Clinical Cancer Research 2000;6:1337-41.
96. Van Dalen EC, van der Pal HJ, Caron HN, Kremer LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD005008.pub2]
97. Van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD005006.pub3]
98. Van Dalen EC, van den Berg H, Raphaël MF, Caron HN, Kremer LC. Should anthracyclines and dexrazoxane be used for children with cancer?. Lancet Oncology 2011;12(1):12-3.
99. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al.Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine 1979;91:710-7.
100. Van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD003917.pub3]
101. Van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD003917.pub3]